In fact, the HGF/Met signalling pathway is importantly involved in pathogenesis of pancreatic cancer, and HGF/Met inhibitors are believed to become in near future crucial therapeutics for pancreatic cancer management.28 Importantly, HGF/SF then activates the signalling components, including Ras, that are required for the signal transduction from the c‐Met receptor towards the ERK pathway (Figure 6A). The gene discussed is MET; the disease is familial pancreatic carcinoma.